Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Procter & Gamble
PGConsumer StaplesGenerated Aug 19, 2026, 09:40 PM UTC
PG (Procter & Gamble) analytical snapshot. Revenue grew +3.3% YoY to $87.03B. 5-year revenue CAGR +1.7%; 10y CAGR +3.3%. Net margin at 18.44% (expanding ▲). Market cap $335.60B at $144.38 per share. Trailing P/E 21.81, P/S 3.86, P/B 6.18. EV/Operating income ≈ 17.69 (EV $349.42B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -7 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Aug 4, 2026. Latest quarterly report (10-Q) filed Apr 24, 2026. 14 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Aug 4, 2026.
- Latest quarterly report (10-Q) filed Apr 24, 2026.
- 14 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Procter & Gamble; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 6 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 14 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 12, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 11, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
| Date | Form | Description |
|---|---|---|
| Jul 29, 2026 | 8-K | 8-K |
| Jul 29, 2026 | 8-K | 8-K |
| Jul 29, 2026 | 8-K | FY2526 Q4 AMJ 8-K |
| Jul 14, 2026 | 8-K | 8-K |
| Apr 24, 2026 | 8-K | 8-K |
| Apr 24, 2026 | 8-K | FY2526 Q3 JFM 8-K |
| Apr 14, 2026 | 8-K | 8-K |
| Jan 22, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
1 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 5 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 1.22x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Goodwill is 33% of total assets: Goodwill of $41.28B represents a large share of the balance sheet. If acquired businesses underperform, a non-cash impairment charge could materially impact earnings. Monitor segment performance and acquisition integration metrics.
- Endogenous analysis: 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 20 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 8 disclosure(s) dropped from prior year — reduced reporting granularity.
- Ongoing high-severity risk language: Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $84.28B | $87.03B | $2.75B | +3.3% |
| Operating income | $20.45B | $19.75B | $-703.0M | -3.4% |
| Net income | $15.97B | $16.05B | $72.0M | +0.5% |
| Operating cash flow | $17.82B | $19.56B | $1.74B | +9.8% |
| Capex | $3.77B | $4.41B | $636.0M | +16.9% |
| Total assets | $125.23B | $126.52B | $1.29B | +1.0% |
| Total liabilities | $72.95B | $72.21B | $-736.0M | -1.0% |
| Long-term debt | $25.00B | $22.84B | $-2.15B | -8.6% |
| Cash & equivalents | $9.56B | $9.94B | $386.0M | +4.0% |
| Stockholders equity | $52.28B | $54.31B | $2.03B | +3.9% |
| Inventory | $7.55B | $8.17B | $619.0M | +8.2% |
| Accounts receivable | $6.18B | $6.06B | $-129.0M | -2.1% |
| R&D expense | $2.10B | $2.10B | $0 | 0.0% |
| SG&A expense | $22.67B | $23.92B | $1.25B | +5.5% |
| Interest expense | $439.0M | $756.0M | $317.0M | +72.2% |
| Type | Concepts |
|---|---|
| Added | DeferredStateAndLocalIncomeTaxExpenseBenefit, EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount, EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent, EffectiveIncomeTaxRateReconciliationFdiiAmount, EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost, EffectiveIncomeTaxRateReconciliationTaxContingencies, EffectiveIncomeTaxRateReconciliationTaxCreditsForeign, EffectiveIncomeTaxRateReconciliationTaxCreditsOther, IncomeTaxPaidFederalAfterRefundReceived, IncomeTaxPaidForeignAfterRefundReceived |
| Removed | EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent, EffectiveIncomeTaxRateReconciliationTaxContingenciesOther, IncomeTaxesPaid, IncreaseDecreaseInAccountsPayableAndAccruedLiabilities, IncreaseDecreaseInOtherOperatingCapitalNet, OtherNoncashExpense, RestructuringAndRelatedCostCostIncurredToDate1, UndistributedEarningsOfForeignSubsidiaries |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Restatement of financial statements | high | 5 | 1 | Ongoing |
| Impairment charge | medium | 5 | 8 | Ongoing |
| Restructuring | medium | 5 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
| Related party transactions | low | 5 | 0 | NEW |
Fundamentals
Revenue grew +3.3% YoY to $87.03B. 5-year revenue CAGR +1.7%; 10y CAGR +3.3%. Net margin at 18.44% (expanding ▲).
- Revenue grew +3.3% YoY to $87.03B.
- 5-year revenue CAGR +1.7%; 10y CAGR +3.3%.
- Net margin at 18.44% (expanding ▲).
- Return on equity 29.54%, ROA 12.68%, ROIC 25.60%.
- Gross margin 0.00%, operating margin 22.69%.
- Free cash flow margin 17.40% ($15.15B).
- Net income up ▲ +0.5% YoY.
- Debt/equity 0.43, current ratio 0.68, net debt $13.82B.
- Asset turnover 0.69 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2025 | $84.28B | +0.3% | 0.00 | 24.26 | 18.95 | $14.04B | 30.55 |
| 2026 | $87.03B | +3.3% | 0.00 | 22.69 | 18.44 | $15.15B | 29.54 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 30, 2024 | $21.74B | -0.6% | — | 18.21% |
| Dec 31, 2024 | $21.88B | +2.1% | +0.7% | 21.16% |
| Mar 31, 2025 | $19.78B | -2.1% | -9.6% | 19.06% |
| Sep 30, 2025 | $22.39B | +3.0% | +13.2% | 21.22% |
| Dec 31, 2025 | $22.21B | +1.5% | -0.8% | 19.45% |
| Mar 31, 2026 | $21.23B | +7.4% | -4.4% | 18.52% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $335.60B at $144.38 per share. Trailing P/E 21.81, P/S 3.86, P/B 6.18. EV/Operating income ≈ 17.69 (EV $349.42B).
- Market cap $335.60B at $144.38 per share.
Price & Technicals
Price $144.38 — downtrend (below 200-DMA); 1-month momentum negative. RSI(14) 51.64.
- Price $144.38 — downtrend (below 200-DMA); 1-month momentum negative.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 0.43 (moderate). Liquidity current ratio 0.68 (stretched).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -7
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Procter & Gamble is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+3.3%** YoY to $87.03B..
Peer comparison
Defensive groupHow PG stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Procter & Gamble PG● you | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |